{"filing":{"accession_number":"0001193125-26-426666","cik":"0002091349","ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-19","primary_document":"trax-20261019.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526426666/trax-20261019.htm"},"events":[{"id":36392,"run_id":33556,"accession_number":"0001193125-26-426666","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of common stock on October 19, 2026, and entered into a registration rights agreement with the investors. This is a classic dilutive equity issuance—an unregistered sale of common stock to private investors with registration rights. The materiality is evident from the substantial share count and the company's obligation to register the shares for resale within 30 days, which signals a significant capital raise and shareholder dilution.","company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40795,"accession_number":"0001193125-26-426666","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of common stock on October 19, 2026, and entered into a registration rights agreement with the investors. This is a classic dilutive equity issuance—an unregistered sale of common stock to private investors with registration rights. The materiality is evident from the substantial share count and the company's obligation to register the shares for resale within 30 days, which signals a significant capital raise and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:06:36.804773+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40795,"accession_number":"0001193125-26-426666","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of common stock on October 19, 2026, and entered into a registration rights agreement with the investors. This is a classic dilutive equity issuance—an unregistered sale of common stock to private investors with registration rights. The materiality is evident from the substantial share count and the company's obligation to register the shares for resale within 30 days, which signals a significant capital raise and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:06:36.804773+00:00","company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","filing_date":"2026-10-20"}]}